Showing 5051-5060 of 5957 results for "".
- Independent, Smaller Hospitals Will Need to Make Tough Choices to Survive COVID-19 Financial Crisis: Analysishttps://modernod.com/news/independent-smaller-hospitals-will-need-to-make-tough-choices-to-survive-covid-19-financial-crisis-analysis/2478252/Independent hospitals could need to make drastic decisions such as reducing service lines or workforces to survive the cash crisis caused by the COVID-19 pandemic, a new analysis finds, according to a FierceHealthcare
- Liminal BioSciences Announces Resubmission of Biologics License Application to FDA for Ryplazimhttps://modernod.com/news/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-fda-for-ryplazim/2478254/Liminal BioSciences announced that the company, through its U.S. subsidiary Prometic Biotherapeutics, has filed a resubmission of the biologics license application (BLA) for Ryplazim (plasminogen) (Ryplazim) with the FDA for the treatment of congenital plasminogen deficiency (C-PLGD). “The
- Graybug Vision Appoints Robert Breuil as Chief Financial Officerhttps://modernod.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO. “I am excited to welcome Robert Breuil to the Gray
- CEO Expects Pfizer Will Know By October If COVID-19 Vaccine Workshttps://modernod.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/Pfizer CEO Albert Bourla said that late-stage study results could be available by the end of October for a coronavirus vaccine it is co-developing with BioNTech, adding “we should have enough [data]…to say whether the product works or not.” His remarks come in the wake of the Trump ad
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- Medical Optometry America to Open First Practice Location in Southcentral Pennsylvaniahttps://modernod.com/news/medical-optometry-america-to-open-first-practice-location-in-southcentral-pennsylvania/2478237/Medical Optometry America (MOA) announced their first practice location will open in Shrewsbury, Pennsylvania in late 2020 and will be led by MOA’s Regional Clinical Director Leslie O’Dell, OD, FAAO. As the first national optometric brand focused exclusively on medical eye care, MOA is lau
- Practitioners Should Be Aware of Mask-Associated Dry Eye (MADE)https://modernod.com/news/core-alerts-practitioners-to-mask-associated-dry-eye-made/2478221/Widespread use of face masks has been determined essential to combat COVID-19’s spread, yet is giving rise to a new phenomenon: increased reports of dry eyes. Experts from the Centre for Ocular Research & Education (CORE) are advising eye care professionals on how to recognize mask-associated
- RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020https://modernod.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/RegeneRx Biopharmaceuticals announced that its US joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. According to GtreeBNT, the ARISE-3 trial was delayed a few months due to COVID-19; h
- Hospitals Could Be Facing Lower Patient Volumes For a While due to COVID-19. How Are They Responding?https://modernod.com/news/hospitals-could-be-facing-lower-patient-volumes-for-a-while-due-to-covid-19-how-are-they-responding/2478223/Patient volumes at hospitals have rebounded after major dips in March and April due to the COVID-19 pandemic. But new data show they are still below pre-pandemic levels and could stay there for a while, according to a FierceHealthcare
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M